STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon

STAT PlusOpinionAdam’s Biotech Scorecard Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon The success of the company’s lung disease drug in a mid-stage study is a testament to its approach Manage alerts for this article Email this article Share this article By Adam FeuersteinSept. 10, 2026 Senior Writer, Biotech Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.

He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter.

STAT+ subscribers can sign up here to get it delivered to their inbox. Roivant has proven to be one of the savviest dealmakers in biotech, evidenced once again this week by the strong efficacy achieved by its pipeline drug mosliciguat in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease, or PH-ILD.Advertisement As I wrote Tuesday, the study results could open up a new way to treat the serious lung disease and bolster Roivant’s financial health with a second blockbuster medicine. The drug’s origins are another fascinating aspect to the story.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In biotechnology, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Adam's Biotech Scorecard September 10, 2026 STAT Plus: What to expect from UniQure’s upcoming Huntington’s gene therapy readout Adam's Biotech Scorecard September 3, 2026 STAT Plus: Abivax has still not been acquired. What’s going on? Advertisement Adam's Biotech Scorecard August 27, 2026 STAT Plus: Alnylam’s heart drug troubles take center stage at a cardiology conference Adam's Biotech Scorecard August 20, 2026 STAT Plus: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection Adam's Biotech Scorecard August 20, 2026 STAT Plus: One of the most consequential years for cancer treatment, ever Subscriber Picks